Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 3Gastrointestinal 3Endocrine 3NET 2Genitourinary 2Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 120Mesothelioma 70Solid Tumor 46Solid Tumors 33Retinoblastoma 27Solitary Fibrous Tumor, Pleural 20Sarcoma 17Advanced Solid Tumor 16Advanced Solid Tumors 15Lung Neoplasms 13Small Cell Lung Carcinoma 12Carcinoma, Non-Small-Cell Lung 11Osteosarcoma 9Neuroblastoma 8Ovarian Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumor, Adult 6Colorectal Neoplasms 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Stomach Neoplasms 5Neoplasms 5Melanoma 5Medulloblastoma 5Chondrosarcoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5

Interventions

cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors × Other solid neoplasm × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡